Rare Benign Lesion of Peins
Pseudoepitheliomatous Hyperplasia of the Penis a Very Rare Disease in Egypt
1 other identifier
observational
1
1 country
1
Brief Summary
PEKMB was first named and described by Lortat-Jacob \& Civatte in 1961 and by Bart \& Kopf later. This rare condition is mostly reported in elderly males. The keratotic scales is usually micaceous and resembles psoriasis. Most patients are above 50 years of age and are circumcised later in life, but also reported in younger age group. This mica like scales contains keratin which gets dissolved in 10% potassium hydroxide solution. Disease progression may lead to phimosis. Differential diagnosis of this disease entity include moniliasis, wart, psoriasis ,penile horn, circinate balanitis, erythroplasia of Queyrat, squamous cell epithelioma and verrucous carcinoma. It is primarily a benign entity, it is capable of invasiveness. Bart and Kopf considered it to be in intermediate stage between benign hyperplasia and squamous cell carcinoma. However, the histological spectrum can range from hypertrophic-hyperplastic penile dystrophy to verrucous carcinoma. Fibro sarcoma has been reported developing in a same patient. Etiology is unclear. Despite search for a viral agent, Human Papilloma Virus (HPV) has not been demonstrated and its role in pathogenesis or its transformation to verrucous carcinoma has been proved. The treatment of PEKMB should be conservative when there is no histological evidence of malignancy. All such patients should be followed up. Treatment choices include potent topical steroids, topical 5% 5-flurouracil cream1, 2, cryotherapy, radiotherapy and shaving biopsy plus electro coagulation. When frank malignancy is observed, excision with wide margin is the rule.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 12, 2021
CompletedFirst Submitted
Initial submission to the registry
January 16, 2021
CompletedFirst Posted
Study publicly available on registry
January 26, 2021
CompletedJanuary 26, 2021
January 1, 2021
Same day
January 16, 2021
January 25, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
improvement of the skin lesion
drugs will be given to patient then the effect ,either improvement or worsening will be noticied
1 month after treatment
improvement of associated lesion
patient complained of difficulty and burning micturition which will be seen after treatment
1 month after drug given
Eligibility Criteria
male healthy married
You may qualify if:
- years
- failed medical treatment
You may not qualify if:
- psoriasis
- allergy
- trauma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assuit Medical School
Asyut, Assuit, 71621, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- chief resident of urology
Study Record Dates
First Submitted
January 16, 2021
First Posted
January 26, 2021
Study Start
January 12, 2021
Primary Completion
January 12, 2021
Study Completion
January 12, 2021
Last Updated
January 26, 2021
Record last verified: 2021-01